Close Menu

NEW YORK ─ Molecular diagnostics firm Immunexpress said Tuesday that it has been awarded a grant of up to $599,549 by the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) to develop its host response sepsis test, SeptiCyte Rapid, as a triage tool to help identify SARS-CoV-2 patients with an elevated risk for viral or secondary bacterial sepsis.

SeptiCyte Rapid is a gene expression assay that uses reverse-transcription PCR to quantify the relative expression levels of host response genes isolated from whole blood.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports on how meeting cancellations and related costs are affecting scientific societies.

In a new ruling, Canada's Supreme Court upheld the country's genetic non-discrimination law, the Canadian Press reports.

COVID-19 vaccine developers aim to avoid a complication that has affected efforts to develop vaccines for other diseases, the Wall Street Journal reports.

In PLOS this week: analysis of insertions throughout Shigella genomes, antigen production in malaria parasites, and more.

Jul
14
Sponsored by
Agilent

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
16
Sponsored by
NanoString

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 

Aug
13
Sponsored by
10x Genomics

This webinar will discuss a study that combined single-cell gene expression and spatial gene expression to understand the evolution of sepsis in the kidney at the cellular and molecular level.